AI Article Synopsis
- HIV-infected individuals have a higher risk of developing lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), but the introduction of combination antiretroviral therapy (cART) has improved outcomes significantly.
- A case study highlights a 44-year-old HIV-positive man with DLBCL in the oral cavity who achieved complete remission for two years after receiving immunochemotherapy and cART, despite not having a strong immunological response.
- The effectiveness of cART is crucial for the prognosis of DLBCL in HIV patients, emphasizing the need for careful monitoring of treatment efficacy to guide future therapy options.
Article Abstract
Introduction: HIV-infected patients are affected significantly more frequently by all types of lymphoma, with diffuse large B-cell lymphoma (DLBCL) as the most prevalent histological type. Since the introduction of combination antiretroviral therapy (cART) morbidity and mortality of DLBCL has been markedly reduced, which is primarily interpreted as a result of the drug-mediated immune reconstitution.
Case Report: We present a previously healthy, 44-year-old HIV-infected man with DLBCL of the oral cavity, treated with immunochemotherapy and cART. During HIV-directed treatment, despite the successful virologic response, a satisfactory immunological response was not achieved. However, the patient had a 2-year complete remission after first-line treatment of DLBCL.
Conclusion: Response to cART strongly predicts outcome in patients with DLBCL. Close monitoring of HIV-directed therapy efficacy, especially as to achievement of successful virologic response, independently associated with prolonged survival, is essential for estimating future DLBCL treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436016 | PMC |
| http://dx.doi.org/10.1159/000471847 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!